Athernal Bio

Athernal Bio is a Cambridge-based biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a widespread blood stem cell mutation condition that significantly increases the risk of acute myeloid leukaemia and other haematological cancers.

The company's pipeline comprises three preclinical programmes targeting patients with rare inherited blood disorders, cancer survivors with treatment-induced clonal haematopoiesis, and older adults with age-related disease progression.

No approved therapies currently exist for clonal haematopoiesis.